Rapamycin-induced proteinuria following allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 44, Issue 1, 2009, Pages 63-65

  Hochegger, K ^a   Wurz, E ^b   Nachbaur, D ^a   Rosenkranz, A R ^a   Clausen, J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ACUTE LYMPHOCYTIC LEUKEMIA; ADD ON THERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LABORATORY TEST; LEUKEMIA REMISSION; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEINURIA; SIBLING; TRANSPLANT ASSOCIATED MICROANGIOPATHY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEINURIA; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 67651124735     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.433     Document Type: Article

References (12)

1. Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B. Nephrotic syndrome after hematopoietic cell transplantation: Do glomerular lesions represent renal graftversus-host disease? Clin J Am Soc Nephrol 2006; 1: 685-694.
2. Franco AF, Martini D, Abensur H, Noronha IL. Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007; 39 449-452.
3. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004; 17: 2152-20.
4. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369-391.
5. Oberbauer R, Schena FP, Wali R, Pascoe M, Alberu J, del Carmen Rial M et al. Conversion from Calcineurin Inhibitors to Sirolimus Compared with Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients: 24-Month Safety and Efficacy Results from the CONVERT Trial. Congress of the American Society of Nephrology: San Diego, 2006.
6. Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, Hugo C. Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849-2861.
7. Hochegger K, Jansky GL, Soleiman A, Wolf AM, Tagwerker A, Seger C et al. Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 2008; 19: 1520-1529.
8. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565-577.
9. Aliabadi AZ, Pohanka E, Seebacher G, Dunkler D, Kammerstatter D, Wolner E et al. Development of proteinuria after switch to sirolimus-based immunosuppression in longterm cardiac transplant patients. Am J Transplant 2008; 8: 854-861.
10. Jurado M, Vallejo C, Perez-Simon JA, Brunet S, Ferra C, Balsalobre P et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 701-706.
11. Furlong T, Kiem HP, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008; 14: 531-537.
12. Barama AA. Mechanisms and management of proteinuria in kidney transplant patients. Drugs 2008; 68 (Suppl 1): 33-39.